Personalized Neuro-Adaptive Treatment System for ADHD

A wearable, AI-driven system for treating attention-deficit hyperactivity disorder (ADHD) by adapting to individual brain activity, genomic data, and behavioral patterns, providing a personalized and optimized treatment plan.

The original patent disclosed a method for treating ADHD using a Radix Polygalae extract. However, this approach has limitations, such as a one-size-fits-all approach, lack of real-time monitoring, and limited understanding of individual variability. The new inventive concept addresses these limitations by integrating wearable technology, machine learning, and genomic analysis to provide a more effective and personalized treatment.

The system comprises a wearable device that administers a composition comprising a Radix Polygalae extract, which is configured to monitor and adapt to the subject's brain activity and cognitive performance in real-time. The system utilizes machine learning algorithms to analyze genomic data, brain activity, and behavioral patterns, generating a customized treatment plan. The treatment plan may include a personalized composition comprising a Radix Polygalae extract, which is delivered through a transcranial magnetic stimulation (TMS) device. The system also enables remote monitoring and treatment, allowing for real-time adjustments and optimization.

The new inventive concept introduces a paradigm shift in ADHD treatment by integrating wearable technology, machine learning, and genomic analysis to provide a personalized and optimized treatment plan. This approach is novel and non-obvious compared to the original patent, which relied on a fixed composition and administration method.

Alternative embodiments may include using different types of wearable devices, such as implantable devices or mobile applications, or incorporating additional data sources, such as environmental or social factors. Variations may also include using different machine learning algorithms or incorporating additional therapeutic modalities, such as cognitive training or behavioral therapy.

The personalized neuro-adaptive treatment system has significant commercial potential in the ADHD treatment market, which is projected to reach $25 billion by 2025. The system's ability to provide personalized and optimized treatment plans, combined with its remote monitoring and treatment capabilities, makes it an attractive solution for patients, clinicians, and payers.